Time New York: Mon 10 Dec 01:10 am  |  Save 15% on H&R Block Online


Hill-Rom (HRC) Estimates Strong Revenue Figures for Q1


Hill-Rom Holdings, Inc. HRC reported preliminary, unaudited revenues of approximately $670 million for the first quarter of fiscal 2018, up 5% year over year and up 3% on a constant exchange rate (CER) basis. The revenue figure is higher than the Zacks Consensus Estimate of $656.4 million, which reflects an improvement of 2.9% from the first quarter of 2017.

Moreover, core revenues rose 2%, surpassing the company's year-over-year expectation of flat core revenues. Notably, core revenues exclude foreign currency translations, Mortara, divestitures and other non-strategic assets the company might choose to exit.

Hill-Rom expects fiscal first-quarter adjusted earnings per share (EPS) to surpass the high end of the 77-79 cent band. Notably, the company has excluded the benefits from the latest U.S. tax legislation and other special items from their current EPS expectations. The Zacks Consensus Estimate for first-quarter EPS is pegged at 80 cents.

Meanwhile, the estimate revision trend has been favorable as one estimate moved north over the past two months, with no movement in the opposite direction. In fact, current-year estimates increased by 2 cents to earnings of 80 cents per share. The stock has a Zacks Rank #3 (Hold).

Hill-Rom Holdings Inc Price and EPS Surprise

What Does the Latest Tax Reform Mean?

The latest U.S. tax legislation, which slashes the corporate tax rate from 35% to 21%, is anticipated to benefit the company with a one-time net gain of roughly $50−$75 million in the fiscal first quarter. This gain is majorly due to the revaluation of net deferred tax liabilities, partially offset by the repatriation tax. However, the company does not expect this gain to influence adjusted non-GAAP financial results.

Moreover, the company anticipates a decline of 500 basis points (bps) in effective tax rate of around 29% in fiscal 2018.

Share Price Movement

Over the past three months, Hill-Rom has been trading above the broader industry. The stock has rallied 13.7% as compared to the industry’s gain of 6.2%. Hill-Rom has been seeing an increase in revenues on strong international growth. The company is focused on gaining traction in untapped international markets on successful execution of its strategy, an efficient international team and organizational realignment.

Hill-Rom’s merger and acquisition (M&A) activities are on track. The company actively pursues acquisitions to accelerate growth in five key clinical areas viz. advancing patient mobility, wound care and prevention, surgical, safety and efficiency, clinical workflow solutions and respiratory help.

We are also upbeat about this leading global medical device company’s focus on expansion through product development which is reflected in the rise in its research and development spending. Last November, Hill-Rom outlined impressive long-term growth strategies along with key initiatives. The company also stated its financial goals through fiscal 2020 which buoy optimism.

Key Picks

A few better-ranked stocks in the broader medical sector are Integer Holdings Corporation ITGR, Bio-Rad Laboratories, Inc. BIO and Intuitive Surgical, Inc. ISRG.

Bio-Rad Laboratories flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 25%.

Integer Holdings has a long-term expected earnings growth rate of 15%. The stock carries a Zacks Rank #2 (Buy).

Intuitive Surgical has a long-term expected earnings growth rate of 9.2%. The stock carries a Zacks Rank #2.

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.